Drugs Containing Excipient (Inactive Ingredient) POLYETHYLENE GLYCOLS

Branded drugs containing POLYETHYLENE GLYCOLS excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Blenheim Pharmacal Inc	ESCITALOPRAM OXALATE	escitalopram	10544-968	POLYETHYLENE GLYCOLS
AR Scientific Inc	COLCRYS	colchicine	13310-119	POLYETHYLENE GLYCOLS
STAT Rx USA LLC	AMBIEN	zolpidem tartrate	16590-009	POLYETHYLENE GLYCOLS
STAT Rx USA LLC	WELLBUTRIN	bupropion hydrochloride	16590-246	POLYETHYLENE GLYCOLS
STAT RX USA LLC	OPANA	oxymorphone hydrochloride	16590-767	POLYETHYLENE GLYCOLS

Generic drugs containing POLYETHYLENE GLYCOLS excipient

Company	Ingredient	NDC	Excipient
Roxane Laboratories Inc	zolpidem tartrate	0054-0086	POLYETHYLENE GLYCOLS
West-Ward Pharmaceutical Corp	ergotamine tartrate and caffeine	0143-2120	POLYETHYLENE GLYCOLS
West-ward Pharmaceutical Corp	gemfibrozil	0143-9130	POLYETHYLENE GLYCOLS
Walgreen Company	ranitidine	0363-0362	POLYETHYLENE GLYCOLS
Walgreen Company	loratadine	0363-2092	POLYETHYLENE GLYCOLS

Polyethylene Glycols (PEGs): Market Dynamics and Financial Trajectory

Last updated: April 7, 2026

Polyethylene glycols (PEGs) are a class of water-soluble polymers used as excipients in pharmaceuticals, cosmetics, and industrial applications. Their chemical versatility, extensive regulatory approvals, and broad application base sustain their demand. The market is characterized by steady growth, driven by increasing drug formulations and expanding non-pharmaceutical uses.

Market Size and Growth Outlook

Global PEG market was valued at approximately USD 950 million in 2022. Compound annual growth rate (CAGR) forecasted at 7.3% from 2023 to 2030, reaching USD 1.76 billion by 2030 (Grand View Research, 2023).

Year	Market Size (USD Million)	CAGR (2023-2030)
2022	950	-
2023	1,020	7.3%
2025	1,370
2030	1,760

Market Drivers

Pharmaceutical Applications

PEGs are used as solvents, stabilizers, and drug delivery agents. Their roles have expanded with the development of complex formulations, such as controlled-release tablets and parenteral drugs. The pharmaceutical sector accounted for approximately 65% of PEG demand in 2022.

Consumer Goods and Industrial Use

Applications in cosmetics (creams, lotions), personal care products, and industrial lubricants contribute to growth. The food industry’s use of PEGs for coatings and stabilizers supports steady demand.

Regulatory Environment

U.S. Food and Drug Administration (FDA) recognizes PEGs as Generally Recognized As Safe (GRAS). European Medicines Agency (EMA) approves PEGs for various oral, topical, and injectable formulations. Regulatory alignment facilitates market access globally.

Production and Supply Chain

Key Players

Large-scale manufacturers include BASF, Dow, and Ashland. These companies operate integrated production facilities, with capacity expansion targeted toward high molecular weight PEGs and specialty grades.

Raw Materials and Economics

PEGs are synthesized via ethylene oxide polymerization. Fluctuations in ethylene oxide production, pricing, and environmental regulations impact costs.

Raw Material	Price Trend (2021-2023)	Contribution to Cost (%)
Ethylene oxide	Volatile, with spikes	50-70%
Propylene oxide	Moderate fluctuations	20-30%

Supply Chain Risks

Environmental regulations on ethylene oxide emissions and regional supply constraints—especially in Asia—pose risks. Disruptions due to COVID-19 hampered logistics and raw material access in 2020-2022.

Competitive Landscape

Leading Companies

• BASF SE: Major player with diversified PEG grades.
• Dow Chemical: Focus on specialty PEG derivatives.
• Ashland Global Holdings: Markets PEGs tailored for pharmaceutical and personal care.

R&D Trends

Investment in biodegradable PEGs and derivatives for targeted drug delivery continues. Patent filings for PEG-based conjugates and novel grades increased by 15% annually from 2017-2022.

Financial Trajectory

Revenue Projections

Based on current demand and expansion plans, PEG market revenues are expected to grow at a CAGR of 7.3%. Companies investing in capacities and R&D anticipate higher margins.

Profitability Margins

Gross margins average 25-30%. High molecular weight PEGs and specialty grades command premium prices, with margins up to 35%.

Future Investment Areas

• Capacity building for high molecular weight PEGs
• Development of biodegradable grades
• Expansion into emerging markets (India, Southeast Asia)

Policy and Regulatory Impacts

Policymakers’ focus on environmental sustainability affects ethylene oxide regulations; stricter emission controls escalate production costs for manufacturers. Market entry for new producers requires compliance with extensive safety standards and approvals.

Key Challenges

• Raw material cost volatility
• Regulatory restrictions on ethylene oxide emissions
• Competition from alternative polymers (e.g., poloxamers)

Opportunities

• Growing pharmaceutical pipeline worldwide
• Increased adoption in biologics formulations
• Rising use in cosmetic and personal care products

---

Key Takeaways

• The PEG market is projected to reach USD 1.76 billion by 2030, with a CAGR of 7.3%.
• Pharmaceutical applications dominate, comprising about 65% of demand.
• Major producers include BASF, Dow, and Ashland, facing supply and regulation headwinds.
• Raw material volatility and strict environmental policies present significant risks.
• Continuous R&D and capacity expansion are core to growth strategies.

---

FAQs

1. What drives demand for PEGs in pharmaceuticals?
PEGs facilitate drug solubilization, improve bioavailability, and enable controlled-release formulations, expanding their use in injectable and oral drugs.

2. How do regulatory policies impact PEG supply?
Regulations on ethylene oxide emissions increase production costs, limit supply, and influence the geographic distribution of manufacturing capacity.

3. What are the main cost components for PEG production?
Ethylene oxide constitutes the majority of raw material costs, with additional expenses from energy, labor, and regulatory compliance.

4. Why are high molecular weight PEGs more expensive?
They require extended synthesis processes, are less commonly produced, and meet specific pharmaceutical requirements, thereby commanding premium prices.

5. What new market segments are emerging for PEGs?
Biologics, advanced drug delivery systems, biodegradable applications, and personal care products are expanding opportunities for PEG derivatives.

---

References

1. Grand View Research. (2023). Polyethylene glycol market size, share & trends analysis report.
2. U.S. Food and Drug Administration (FDA). (2022). Polymers in drug delivery.
3. European Medicines Agency (EMA). (2022). Summary of product characteristics for PEG-containing medicines.